Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer96
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma43
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats38
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway37
Artesunate overcomes lenvatinib resistance by inhibiting the STAT3/SLC25A27 pathway and promoting ferroptosis in hepatocellular carcinoma33
The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention31
MiR-124-3p Suppresses Glioma Cells Progression by Targeting STAT3/NAMPT and Inhibiting AKT/ERK Signaling30
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy29
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression29
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis27
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression20
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%19
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer18
FHOD3 Promotes the Progression of Lung Cancer by Regulating the Caspase-3-Mediated Signaling Pathway18
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT17
Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE's Contribution to Immunosuppressive Microenvironment17
DDX18 as a Prognostic Biomarker Associated with Pan-Cancer Immune Infiltration and Drug Sensitivity17
A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine17
0.060849905014038